20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Belite Bio Inc ADR (BLTE) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 41 employees. Its market capitalization is roughly $7 billion. In the fiscal year ended 2025-12-31, BLTE reported $0M in revenue and ($78M) in net income.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($119M) | ($84M) | ($40M) | ($32M) | ($13M) | ($10M) | ($6M) |
| Operating Margin % | — | — | — | — | — | — | — |
| Net Income | ($102M) | ($78M) | ($36M) | ($32M) | ($13M) | ($10M) | ($6M) |
| Net Margin % | — | — | — | — | — | — | — |
| EBITDA | ($114M) | ($77M) | ($36M) | ($31M) | ($12M) | ($10M) | ($6M) |
| Earnings Per Share (EPS) | $-2.79 | $-2.31 | $-1.18 | $-1.19 | $-0.63 | $-0.40 | $-0.62 |
| Shares Outstanding (M) | 40M | 34M | 31M | 27M | 20M | 24M | 9M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($35M) | ($33M) | ($28M) | ($23M) | ($18M) | ($16M) | ($11M) | ($10M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($28M) | ($27M) | ($25M) | ($22M) | ($16M) | ($14M) | ($10M) | ($9M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($35M) | ($27M) | ($31M) | ($22M) | ($16M) | ($14M) | ($8M) | ($9M) |
| Earnings Per Share (EPS) | $-0.71 | $-0.68 | $-0.76 | $-0.65 | $-0.50 | $-0.44 | $-0.32 | $-0.28 |
| Shares Outstanding (M) | 40M | 40M | 34M | 33M | 33M | 32M | 31M | 31M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | — | ($37M) | ($29M) | ($30M) | ($11M) | ($7M) | ($4M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | — | ($37M) | ($29M) | ($30M) | ($12M) | ($8M) | ($4M) |
| FCF Margin % | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash from Operations (CFO) | $0M | ($5M) |
| Capital Expenditures (CapEx) | $0M | $0M |
| Free Cash Flow (FCF) | $0M | ($5M) |
| FCF Margin % | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Total Assets | $792M | $781M | $152M | $95M | $44M | $18M | $26M |
| Cash & Cash Equivalents | — | $353M | $32M | $88M | $42M | $17M | $26M |
| Total Liabilities | $15M | $10M | $6M | $4M | $3M | $33M | $33M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $777M | $770M | $146M | $90M | $42M | ($15M) | ($7M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BLTE viewer.
About TickerBase · Data methodology & sources · Privacy · Terms